
Emmanuel Stylianos Antonarakis MD
Genitourinary Oncology
Professor of Medicine (Oncology), University of Minnesota. Director of Translational Research, Masonic Cancer Center.
Join to View Full Profile
University Of MinnesotaMinneapolis, MN 55455
Dr. Antonarakis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2007 - 2010
- Johns Hopkins UniversityResidency, Internal Medicine, 2004 - 2007
- The University of Wales College of MedicineClass of 2003
Certifications & Licensure
- MN State Medical License 2021 - 2025
- NH State Medical License 2024 - 2024
- MD State Medical License 2007 - 2022
- NC State Medical License 2020 - 2022
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
- Top Doctors:Baltimore Area Castle Connolly, 2012
- Top Doctors:Washington-Baltimore Castle Connolly, 2012
Clinical Trials
- Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2012 Mar 30
- A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer Start of enrollment: 2013 Jan 18
- 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy Start of enrollment: 2012 Dec 18
- Join now to see all
Publications & Presentations
PubMed
- T-cell Engagers in Prostate Cancer.Chadi Hage Chehade, Zeynep Irem Ozay, Micah Ostrowski, Chiara Mercinelli, Georges Gebrael
European Urology. 2025-03-11 - Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes.Justin Hwang, Pornlada Likasitwatanakul, Sachin Kumar Deshmukh, Sharon Wu, Jason J Kwon
Clinical Cancer Research. 2025-03-03 - Radiotherapeutics, clonal hematopoiesis, and risk of hematologic malignancies: The good, the bad, the ugly.Catherine H Marshall, Emmanuel S Antonarakis, Mrinal M Patnaik
Blood Reviews. 2025-03-01
Journal Articles
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate CancerEmmanuel S Antonarakis, Ashley E Ross, Michael A Gorin, Samuel R Denmeade, Channing J Paller, Kenneth J Pienta, Mario A Eisenberger, JAMA Oncology
Lectures
- Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analy...2019 ASCO Annual Meeting - 6/1/2019
Other
- Germline DNA-Repair Gene Mutations and Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Receiving First-Line Abiraterone and EnzalutamideEmmanuel Antonarakis, MD, European Urology
https://www.doximity.com/articles/aa1e6f6d-be80-4fdc-91e9-2ccae3c99bc3
UpToDate, Wolters Kluwer Health - 2013-04-10
Authored Content
- Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-Resistant Prostate Cancer in the Era of Precision OncologyApril 2018
Press Mentions
- BRCA1 Contribution to Prostate Cancer Called into QuestionFebruary 24th, 2025
- Precision Drug Olaparib May Be Effective Without Hormone Therapy for Some Men with Biochemically Recurrent Prostate CancerAugust 21st, 2024
- Study Shows How Novel Immunotherapy Helps Fight High-Risk Prostate Cancer, ET HealthWorldApril 8th, 2023
- Join now to see all
Professional Memberships
- Member
Other Languages
- French, Greek
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: